PROGRAM BOOK

37 Annual Scientific Meeting Of Indonesian Ophthalmologist Association

Surabaya, 5 - 7 July 2012

37th Annual Scientific Meeting of Indonesian Ophthalmologist Association

Grand City Convention & Exhibition Surabaya, 05 - 07 July 2012

IOA

CENDO
DIAMOND SPONSOR

Alcon
PLATINUM SPONSOR

OPTIK TUNGGAL
GOLD SPONSOR

TRIASTRI MEDITAMA
SILVER SPONSOR

KMN
Klinik Mata Nusantara
SILVER SPONSOR

ORGANIZING COMMITEE

Prof. Dr. Nila F. Moeloek,, MD
IOA President

Djiwatmo, MD
Chairman of IOA East Java

Ari Djatikusumo, MD
Head of DP3 PP Perdami

Johan Hutauruk, MD
Head of Div. PIT PP Perdami

ADVISOR

Prof. Wisnujono Soewono, MD
Prof. Diany Yogiantoro, MD
Prof. Hamidah M Ali, MD
Prof. Dr. Gatut Suhendro, MD
Prof. Rowena G Hoesin, MD
Prof. Sjamsu Boediono, MD

EXECUTIVE COMMITEE

Chairman
Wimbo Sasono, MD
Vice Chairman
Hendrian Dwikoloso S, MD
Yulia Primitasari, MD
Secretary
Randi Montana, MD
Ria Sandy Deneska, MD
Treasurer
Luki Indriaswati, MD
Ismi Zuhria, MD

SCIENTIFIC PROGRAM COMMITEE

Ratna Doemilah, MD
Trisnowati Taib Saleh, MD
Moestidjab, MD
Prillia Tri Suryani, MD
Eddyanto, MD
Nurwasis, MD
Evelyn Komaratih, MD
Gatot Suhartono, MD
Rozalina Loebis, MD
Sauli Ary Widjaya, MD
Rini Kusumawar Dhany, MD

PUBLICATION & DOCUMENTATION
Sutjipto, MD
Moegiono M. Oetomo, MD
Delfitri Lutfi, MD

REGISTRATION
Reni Prastyani, MD
Indri Wahyuni, MD
Irma Praminiarti, MD

TRANSPORTATION & ACCOMMODATION
M. Firmansjah, MD

AVIT & EQUIPMENT
Dicky Hermawan, MD
Sahata Poltak Napitupulu, MD

BANQUET
Lukisiari Agustini, MD
Imama Qosida, MD

FUND RAISING & EXHIBITION
Dwi Ahmad Yani, MD
Fitria Romadiana, MD

CEREMONY
Harijo Wahjudi, MD

SECURITY
Empi Irawan, MD
M. Syamsudin, MD

MEDICAL EMERGENCY
Christina Aritonang, MD

37th Annual Scientific Meeting Of Indonesian Ophthalmologist Association

Surabaya, 5 - 7 July 2012

CONTENT

SYMPOSIUM 5 : AMD
CRYSTAL ROOM 1 : 15.30 - 17.00
MODERATOR : Gatut Suhendro
CO MODERATOR : Ramzi Amin

TIME	SPEAKER	FROM	TOPIC
15.30 - 15.45	Paisan Ruamviboonsuk	Thailand	Updates on PCV
15.45 - 16.00	Shi Bo Tang	PR. China	Basic Disease Mechanisms of Choroidal Neovascularization: Therapeutic Implications
16.00 - 16.25	Habibah S Muhiddin	FK Unhas Makasar	OCT and FA in AMD
16.25 - 16.30	Tri Wahyu Widayanti	FK UGM Jogjakarta	Intravitreal anti VEGF
16.30 - 16.45	Gilbert Simanjuntak	RS Cikini Jakarta	Updates on AMD
16.45 - 17.00	Safarudin Refa	FK UB Malang	Supplementation in AMD

UPDATES ON AMD

Gilbert W S Simanjuntak
RS Cikini/FK-UKI
Jakarta

What is new...

- In diagnostic
- In therapeutic

… prognostic

Diagnostic

- Autofluorescence imaging
- High resolution OCT
- Combined OCT, SLO and mfERG
- Macular perimetry (+mfERG)
- ….

  - When to do, indication(s)

ANTI-ANGIOGENESIS in EYE

The man who doesn't know the history, they don't have future

Extrapolate from cancer treatment (NV)

Folkman, J. Tumor angiogenesis: therapeutic implications. Science 1971,18:1182-6

Miller et al. VEGF is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574–584.

The Past AND Present

- NON-PHARMACOTHERAPY:
  - MPS, and its role currently(foveolar, juxtafoveolar, extrafoveolar, paramacular, extramacular, etc). Recurrency 54% at long term
  - SST, and its role currently (type 1 & 2)



- PHARMACOTHERAPY COMBINATION (10 yrs)
  - PDT (photosensitizer)/TTT (w/wo photosensitizer), alone/combined
    - Predominantly classic, minimally classic, occult CNV. Rather preserving than improving VA

- PHARMACOTHERAPY:
  - Pegabtanib, FDA Dec 2004, 6 wks interval IV, rather preserving than improving VA
  - July 2005, Systemic Avastin for the Treatment of Neovascular AMD (SANA) trial as well as case reports of intravitreal bevacizumab use supported by optical coherence tomography (OCT) documentation.
  - …

Commencing the Anti-VEGF era

Anti-VEGF Trial

- Year 2006 (bevacizumab available 2005, used with multiple uncontrolled studies. No obvious evidence of side effects or safety issues, OFF LABEL use)
  - Marina study : a placebo-controlled trial of ranibizumab
  - Anchor study : a randomized comparison of ranibizumab and photodynamic therapy
- Ranibizumab approved June 2006

Trial (ctd.)

- Medicare Part B (2008)
  - bevacizumab accounted for 58%, ranibizumab for 41%, and macugen 1%

    Am J Ophthalmol 2011;151:887-95.
  - Indonesia (?)
- PRONTO study
- PIER study
  - Rani- dosing, 1 year result etc

6 years of OFF LABEL use of avastin in US (2011)

Other issues

Government Driven Research

- Bevacizumab *vs* Ranibizumab, non-inferiority trial
  - CATT study : NIH, US
    - Primary outcome : there were equivalent mean changes in visual acuity averaged over the 1-year period
    - noninferiority limit of 5 letters on the eye chart
  - IVAN study : UK
    - Noninferiority limit was 3.5 letters

CATT study 1 year (beva- *vs* rani-)

- Administered monthly : equivalent (VA 8.0 vs 8.5 gained)
- Administered as needed : equivalent (5.9 vs 6.8 gained)
- Rani- monthly *vs* as needed : equivalent
- Beva- monthly *vs* as needed : inconclusive



Mean (±SE) Change in Visual-Acuity Score from Baseline (no. of letters)					
Ranibizumab monthly	+3.6±0.5	+6.1±0.7	+6.6±0.8	+7.5±0.9	+8.5±0.8
Bevacizumab monthly	+4.3±0.6	+6.1±0.7	+7.3±0.9	+7.7±1.0	+8.0±1.0
Ranibizumab as needed	+3.3±0.6	+5.6±0.7	+5.8±0.7	+7.2±0.7	+6.8±0.8
Bevacizumab as needed	+3.2±0.5	+5.6±0.7	+5.8±0.8	+7.1±0.9	+5.9±1.0

CATT Study. N Engl J Med 2011;364:1897-908

CATT study 1 year (ctd.)

- mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 µm) than in the other groups (152 to 168 µm, P = 0.03 ANOVA)



Mean (±SE) Change in Thickness at Fovea from Baseline (µm)	Wk 4	Wk 8	Wk 12	Wk 24	Wk 52
Ranibizumab monthly	−151±9	−173±9	−175±10	−178±10	−196±11
Bevacizumab monthly	−131±9	−147±9	−151±10	−156±11	−164±11
Ranibizumab as needed	−153±9	−157±10	−163±11	−157±11	−168±11
Bevacizumab as needed	−126±8	−137±9	−138±10	−139±10	−152±11

Patients concern *vs* doctors concern

CATT study 1 year (ctd.)

- Rates of death, myocardial infarction, and stroke were similar (P>0.20)
- Serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab.
  Needs cautious interpretation
- Average cost of drug/patient ($) —
  - Monthly rani- 23,400 39x
  - Monthly beva- 595
  - As needed rani- 13,800
  - As needed beva- 385

CATT study 2 year

- To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years (longer effects)
- To describe the impact of switching to as-needed treatment after 1 year of monthly treatment.
- As previous design (4 treatment arms).
  - At 1 year, patients initially assigned to monthly treatment were reassigned randomly to monthly or as-needed treatment, without changing the drug assignment
- **Main Outcome Measures:** Mean change in VA

CATT Research Group. Ophthalmology 2012

- For 2 years, mean gain in visual acuity was similar, P=0.21
- administered as needed : equivalent (5.9 vs 6.8 gained)
- Rani- monthly *vs* as needed : equivalent
- Beva- Administered monthly *vs* as needed : inconclusive



- Mean gain was greater for monthly than for as-needed treatment
- Switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2 (2.2 letters; *P 0.03) and a* lower proportion without fluid (19%; *P 0.0001).*



- The proportion without fluid ranged from 13.9% in the bevacizumab-as-needed group to 45.5% in the ranibizumab monthly group (drug, *P 0.0003; regimen, P 0.0001).*



- Rates of death and arteriothrombotic events were similar
- Proportions of patients with 1 or more systemic serious adverse events was higher with bevacizumab than ranibizumab (39.9% vs. 31.7%; adjusted risk ratio, 1.30; 95% CI, 1.071.57; *P 0.009). (Inconsistent with IVAN Study result)*

Read cautiously, since older patients (>80 years) more in beva- arm than rani- arm

IVAN Study 1 year

- 4 arm, noninferiority limit was 3.5 letters
- The comparison of visual acuity at 1 year between bevacizumab and ranibizumab was inconclusive.
- Visual acuities with continuous and discontinuous treatment were equivalent.
- Other outcomes are consistent with the drugs and treatment regimens having similar efficacy and safety.

Ophthalmology 2012. Epub ahead 2012 May 11

- Fewer participants receiving bevacizumab had an arteriothrombotic event or heart failure (odds ratio [OR], 0.23; 95% CI, 0.05 to 1.07; *P 0.03).*
- There was no difference between drugs in the proportion experiencing a serious systemic adverse event (OR, 1.35; 95% CI, 0.80 to 2.27; *P 0.25).*
- Serum VEGF was lower with bevacizumab (GMR, 0.47; 95% CI, 0.41 to 0.54; P0.0001) and higher with discontinuous treatment (GMR, 1.23; 95% CI, 1.07 to 1.42; *P 0.004).*

Beva- vs rani- compound, to consider

- Monoclonal antibodi
- Total (149 kDa) vs fractionated (48kDa).
- Fc role, less easy penetration and longer effect *vs* easier penetration through ILM and shorter effect N Engl J Med 2006;355(14):1409 –1412
- The intravitreal half-lives of rani- and beva-, were estimated to be 3.2 and 5.6
  Retina. 2012 Mar;32(3):434-57.



Aflibercept (VTE)

- VEGF trap-eye 2 mg (0.05 ml; EYLEA™) injected either monthly or every other month was comparable to monthly dosing of ranibizumab in visual acuity gain and safety.
- Nov 18 2011, FDA approval for the treatment of patients with neovascular age-related macular degeneration.

  Nat Rev Drug Discov. 2012
- The FDA's Ophthalmic Drug Advisory Committee recommended for monthly inj for 3 months then every 2 months dosing

EYLEA (ctd)

- A 115-kDa recombinant fusion protein consisting of the VEGF-binding domains of human VEGF receptors 1 and 2 fused to the Fc domain of human IgG1 and inhibits all VEGF isoforms and placental growth factor.
- Its high VEGF affinity attributes to the binding sequences from the native receptors VEGFR1 and VEGFR2

Every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept

on selected patients who had a poor response to monthly therapy

- bevacizumab every 2 weeks has binding levels that were superior to monthly dosing with ranibizumab at a dose of 0.5 mg and potentially superior to the levels achieved when ranibizumab was dosed monthly at a dose of 2.0 mg.
- The VTE displayed superior binding levels for both peak and trough levels even when compared with ranibizumab doses given every 2 weeks.
- half-lives of ranibizumab, bevacizumab, and the VTE were estimated to be 3.2, 5.6, and 4.8 days, respectively

(PS… beva 1 mg monthly ?)

Retina. 2012 Mar;32(3):434-57.

Several considerations …..

- Patient dyscomfort for 2 years
  - intravitreal inj. for 2 years? Shorter or longer interval
- Combination therapy with steroid ?
  - Longer acting ? PDT and IVTA result



why steroid ?

Process of Angiogenesis

- NV : proliferation of new vessels
- Development of new blood vessels from pre-existing, mature vascular network
  - Distinct from vasculogenesis (de novo blood vessel growth in development)
- Follows stochastic series of events, each step dependent upon the previous
  - Inhibition of any step aborts the process





Steps in Neovascularization



1. Angiogenic signal
   - VEGF
   - FGF
   - PEDF
   - Inflammatory cytokines*

* Br J Ophthalmol. 2011 Dec;95(12):1631-7. Epub 2011 May 5.

Steps in Neovascularization



1. Angiogenic signal
2. Endothelial cell activation
3. MMP induction
4. Extracellular matrix remodeling
5. Vascular endothelial cell (VEC) migration
6. VEC proliferation
7. Lumen formation
8. Vascular stabilization

VEGF blockers

- Specific VEGF inhibition
- Antiproliferative-antipermeability effects
- Intravitreal route of administration
- Treatment approaches
  - Monotherapy
  - Combination therapy

Corticosteroid Use for Wet AMD

- Principal effects
  - Stabilizes blood-retinal barrier
  - Resorption of exudation
  - Down regulation of inflammatory stimuli
- Secondary effect
  - Antiangiogenesis



- Intra vitreal injection
  - Triamcinolone acetate (Kenacort™)
  - Duration 4-6 months
- Intra vitreal implants
  - Fluocinolone (Retisert™) : 3 years
  - Dexamethasone (Ozurdex®) : 3-4 months

Factors to consider in steroid : limited data available for CNV

Radio therapy…

- Logic behind
- Technique and limitations
  - Pre-retinal
  - Sub-retinal/foveal : equal treatment and control in progression. Br J Ophthalmol 2005;89:1045–1051

Pigment Epithelial Detachment











(?) PED Treatment



Reason for vision loss in ARMD

Table 1. Physiologic processes involving VEGF [adapted from ref. 13]

Alveolar septal cell survival
Bone growth and fracture healing
Cardiac development
Dendritic cell differentiation and function
Endothelial cell proliferation, survival and recruitment
Female reproductive function
Glomerulogenesis and kidney function
Induction of plasminogen activator, endothelial nitric oxide and matrix metalloproteinases
Lung maturation
Maintenance of the microvasculature in many organs
Monocyte/macrophage chemoattraction
Neovascularization following myocardial infarction and stroke
Neural cell survival
Pancreatic islet cell survival
Protection of hepatic cells from toxic damage
Skeletal muscle regeneration
Trophic support of choriocapillaris
Vasodilation
Vascular permeability
Wound healing

Ophthalmologica 2012;227(suppl 1):2–10

mauliate

(THANK YOU)

D.3.1.12

Certificate of Attendance

This is to Certify that

GILBERT WS SIMANJUNTAK, MD

Has attended as

SPEAKER

In The 37th Annual Scientific Meeting
Of Indonesian Ophthalmologist Association

Surabaya, July 5 – 7, 2012

37th

Wimbo Sasono, MD
Chairman of The Organizing Committee

Prof. Nila F. Moeloek, MD, PhD.
President of Indonesian Ophthalmologist Association

SK PB IDI No. : 2228/PB/A.4/06/2012 :
Participant 12 SKP IDI, Speaker/Instructor 12 SKP IDI, Moderator 4 SKP IDI, Committee 2 SKP IDI